Flightpath Biosciences Inc. News - Profile and Newsroom at Send2Press Newswire

Flightpath Biosciences Inc. Newsroom - Profile and News Archive

Flightpath Biosciences is developing microbiome-targeted therapeutics and advanced biomarker-based diagnostics for the treatment of infectious diseases. Flightpath's mission is to transform patient's lives with medicines developed using a multidisciplinary approach to human and pathogen biology.

Engage with Flightpath Biosciences Inc.

Press Releases from Flightpath Biosciences Inc. :

Flightpath Biosciences Launches via Illumina Accelerator to Conduct Largest Clinical Biomarker Study in Lyme Disease

Feb 9, 2021 7:50 AM EST

BERKELEY, Calif., Feb. 9, 2021 (SEND2PRESS NEWSWIRE) — Flightpath Biosciences, a life sciences company, launched today claiming a spot in Illumina Accelerator’s second global class to develop diagnostics and microbiome-targeted therapeutics to treat rare pathogen-driven diseases. The company has operated in stealth since its founding in mid-2019 and has built a pipeline of drug candidates for a wide range of diseases, starting with acute and Persistent Lyme Disease (PLD).